⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6536480 | 0.88 | MPO (0.31) | — | |
| SCHEMBL8046859 | 0.73 | — | — | |
| SCHEMBL6681436 | 0.73 | ALDH1A1 (0.34) | — | |
| SCHEMBL789177 | 0.71 | — | — | |
| SCHEMBL1377643 | 0.69 | — | — | |
| SCHEMBL6810692 | 0.63 | — | — | |
| Water SCHEMBL30522000 | 0.58 | MPO (0.34) | — | |
| SCHEMBL2523527 | 0.57 | DHFR (0.34) | — | |
| SCHEMBL4091048 | 0.53 | — | — | |
| SCHEMBL7535813 | 0.53 | KDM4E (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2308 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630827-B2 | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies | ROGCON, INC. (US) | 2026-05-19 | — | — | US | claimed |
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250257360-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | UNIV OKLAHOMA (US) | 2025-08-14 | — | — | US | claimed |
| CN-113151261-B | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2025-06-17 | — | — | CN | claimed |
| US-20250179503-A1 | METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS | PRAXIS PREC MEDICINES INC (US) | 2025-06-05 | — | — | US | claimed |
| US-20250146073-A1 | METHODS FOR THE TREATMENT OF SCN2A-RELATED DISORDERS | PRAXIS PREC MEDICINES INC (US) | 2025-05-08 | — | — | US | claimed |
| EP-4504945-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | The Board of Regents of the University of Oklahoma (US) | 2025-02-12 | — | — | EP | claimed |
| EP-4499835-A2 | METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS | Praxis Precision Medicines, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| EP-4473113-A2 | METHODS FOR THE TREATMENT OF SCN2A-RELATED DISORDERS | Praxis Precision Medicines, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| US-12146139-B2 | Oligonucleotide interference treatments of prostate cancer | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2024-11-19 | — | — | US | claimed |
| WO-2016075339-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2016-05-19 | — | — | WO | claimed |
| EP-3020813-A1 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | Neurovision Pharma GmbH (DE) | 2016-05-18 | — | — | EP | claimed |
| US-9334495-B2 | Minor groove binder (MGB)-oligonucleotide miRNA antagonists | ELITECHGROUP B.V. (NL) | 2016-05-10 | — | — | US | claimed |
| EP-2547769-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | Elitech Holding B.V. (NL) | 2013-01-23 | — | — | EP | claimed |
| WO-2012099630-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A RETROVIRUS INFECTION | UNIVERSITY OF ROCHESTER (US) | 2012-07-26 | — | — | WO | claimed |
| US-20110172289-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | ELITECH HOLDING B.V. | 2011-07-14 | — | — | US | claimed |
| WO-2011066312-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | ELITECH HOLDING B.V. (NL) | 2011-06-03 | — | — | WO | claimed |
| US-7067497-B2 | Modulation of telomere length by oligonucleotides having a G-core sequence | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-27 | — | — | US | claimed |
| US-20040049022-A1 | Composition & methods for treatment and screening | NYCE JONATHAN W (US) | 2004-03-11 | — | — | US | claimed |
| WO-2004011613-A2 | COMPOSITION & METHODS FOR TREATMENT AND SCREENING | EPIGENESIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | claimed |